Targeted Oncology

Moving Beyond Transfusion Dependence in the MDS Landscape

According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion independence compared with 15.0% of patients treated with placebo. Respondents ...
Targeted Oncology

FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer

The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...
Healio

Topical solution for chronic fungal nail infection consistently effective across races

Efinaconazole 10% solution was found to be a safe and effective treatment of chronic fungal nail infections among patients with skin of color, according to a study published in the Journal of Drugs in ...
Nasdaq

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...
Infectious Disease Advisor

FDA Grants Fast Track Status to BNT113 for HPV16+ Head and Neck Cancer

The FDA grants Fast Track designation to BNT113 for treating HPV16+ head and neck squamous cell carcinoma expressing PD-L1 in the first-line setting.